Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06457789

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

Led by Amsterdam UMC, location VUmc · Updated on 2025-04-02

34

Participants Needed

1

Research Sites

186 weeks

Total Duration

On this page

Sponsors

A

Amsterdam UMC, location VUmc

Lead Sponsor

F

Foundation for the National Institutes of Health

Collaborating Sponsor

AI-Summary

What this Trial Is About

The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor. This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.

CONDITIONS

Official Title

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed NSCLC
  • Tumor stage T1-4N0-2 with lesion size of 2 cm or larger at restaging FDG PET/CT
  • Planned surgery after chemo-immunotherapy following routine guidelines
  • Able and willing to give written informed consent
  • 18 years of age or older at time of consent
  • Measurable disease based on RECIST 1.1 criteria
  • ECOG performance status 0-1 and operable based on pulmonary function or exercise tests
Not Eligible

You will not qualify if you...

  • Patients considered inoperable
  • Patients who have had spleen removal (splenectomy)
  • Received any vaccination within 14 days before enrollment
  • Need systemic corticosteroids over 10 mg prednisone equivalent daily or other immunosuppressive drugs within 14 days before day 0
  • Have psychiatric or substance abuse conditions that interfere with trial participation
  • Pregnant, breastfeeding, or planning to conceive during the trial period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Amsterdam UMC, location VUmc

Amsterdam, North Holland, Netherlands, 1081 HV

Actively Recruiting

Loading map...

Research Team

M

Maarten Slebe, Msc.

CONTACT

I

Idris Bahce, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here